BioMimetic gets FDA panel nod by slim margin

An FDA advisory committee Thursday endorsed BioMimetic Therapeutics' ($BMTI) experimental drug-device combination product Augment, which is intended as an alternative to autograft procedures for patients who undergo certain foot and ankle repair surgeries, Dow Jones reported. The panel voted 10-8 that the Franklin, TN-based company's product provides greater benefits than risks, 12-6 in support of the safety of the treatment and 10-8 on the question of effectiveness, according to the news service. The FDA will weigh the committee's votes in deciding whether to approve the treatment. Yet the relatively slim margin of victory for BioMimetic doesn't clear up whether the agency will ultimately support the firm's application for approval. BioMimetic release | Report

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.